{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:08:53Z","timestamp":1788988133025,"version":"build-2803163510"},"reference-count":121,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003323","name":"ANRS Emerging Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.annder.2026.103507","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T20:09:56Z","timestamp":1782331796000},"page":"103507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["2024 guidelines (S3) for the therapeutic management of patients with genital herpes"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5772-3504","authenticated-orcid":false,"given":"E.","family":"Joly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lothmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9734-7451","authenticated-orcid":false,"given":"S.","family":"Fouere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3962-8869","authenticated-orcid":false,"given":"A.","family":"Bertolotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2026.103507_b0005","unstructured":"Guidelines for the management of symptomatic sexually transmitted infections. https:\/\/www.who.int\/publications-detail-redirect\/9789240024168. [Accessed 14 March 2023]."},{"key":"10.1016\/j.annder.2026.103507_b0010","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.annder.2016.09.009","article-title":"Genital herpes","volume":"143","author":"Milpied","year":"2016","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2026.103507_b0015","unstructured":"Recommandations pour la pratique clinique (RPC). Haute Autorit\u00e9 de Sant\u00e9. https:\/\/www.has-sante.fr\/jcms\/c_431294\/fr\/recommandations-pour-la-pratique-clinique-rpc. [Accessed 13 May 2023]."},{"key":"10.1016\/j.annder.2026.103507_b0020","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1128\/AAC.38.2.174","article-title":"A randomized, double-blind, comparative trial comparing high- and standard-dose oral acyclovir for first-episode genital herpes infections","volume":"38","author":"Wald","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.annder.2026.103507_b0025","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0002-9343(82)90118-8","article-title":"Oral acyclovir in the treatment of genital herpes. Preliminary report of a multicenter trial","volume":"73","author":"Fiddian","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.annder.2026.103507_b0030","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(82)90658-4","article-title":"Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes","volume":"2","author":"Nilsen","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2026.103507_b0035","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jama.1984.03350090023017","article-title":"Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection","volume":"252","author":"Mertz","year":"1984","journal-title":"J Am Med Assoc"},{"issue":"Suppl B","key":"10.1016\/j.annder.2026.103507_b0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/jac\/12.suppl_B.61","article-title":"Current status and prospects for oral acyclovir treatment of first episode and recurrent genital herpes simplex virus","volume":"12","author":"Bryson","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.annder.2026.103507_b0045","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00007435-199709000-00007","article-title":"Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group","volume":"24","author":"Fife","year":"1997","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.annder.2026.103507_b0050","first-page":"28","article-title":"Acyclovir in first attacks of genital herpes and prevention of recurrences","volume":"62","author":"Mindel","year":"1986","journal-title":"Genitourin Med"},{"key":"10.1016\/j.annder.2026.103507_b0055","first-page":"33","article-title":"Efficacy of oral treatment with acyclovir and co-trimoxazole in first episode genital herpes","volume":"62","author":"Kinghorn","year":"1986","journal-title":"Genitourin Med"},{"key":"10.1016\/j.annder.2026.103507_b0060","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010684.pub2","article-title":"Interventions for men and women with their first episode of genital herpes","author":"Heslop","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.annder.2026.103507_b0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4111\/icu.20230275","article-title":"Korean sexually transmitted infection guidelines 2023 revision, guideline update of viral infections: genital herpes and anogenital warts","volume":"65","author":"Kim","year":"2024","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.annder.2026.103507_b0070","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jiac.2021.07.015","article-title":"Asian guidelines for genital herpes","volume":"27","author":"Sindhuja","year":"2021","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.annder.2026.103507_b0075","doi-asserted-by":"crossref","DOI":"10.1590\/0037-8682-663-2020","article-title":"Brazilian Protocol for Sexually Transmitted Infections, 2020: infections that cause genital ulcers","volume":"54","author":"Ramos","year":"2021","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.annder.2026.103507_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.annder.2026.103507_b0085","unstructured":"Canada A de la sant\u00e9 publique du. Guide sur l\u2019Herp\u00e8s g\u00e9nital: Traitement et suivi; 2021. https:\/\/www.canada.ca\/fr\/sante-publique\/services\/maladies-infectieuses\/sante-sexuelle-infections-transmissibles-sexuellement\/lignes-directrices-canadiennes\/virus-herpes-simplex\/traitement-suivi.html. [Accessed 14 March 2023]."},{"key":"10.1016\/j.annder.2026.103507_b0090","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/0956462415580512","article-title":"2014 UK national guideline for the management of anogenital herpes","volume":"26","author":"Patel","year":"2015","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.annder.2026.103507_b0095","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1177\/0956462417727194","article-title":"2017 European guidelines for the management of genital herpes","volume":"28","author":"Patel","year":"2017","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.annder.2026.103507_b0100","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1701-2163(16)32805-5","article-title":"Genital herpes: gynaecological aspects","volume":"30","author":"Money","year":"2008","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.annder.2026.103507_b0105","first-page":"34","article-title":"Valaciclovir hydrochloride versus aciclovir in the treatment of first-episode genital herpes: a controlled, randomized open trial","volume":"1","author":"Lai","year":"2000","journal-title":"Chin J Dermatovenereol"},{"key":"10.1016\/j.annder.2026.103507_b0110","unstructured":"Guidelines for the management of genital herpes in New Zeland; 2017. https:\/\/guidelines.stief.org.nz\/herpes. [Accessed 14 March 2023]."},{"key":"10.1016\/j.annder.2026.103507_b0115","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/0002-9343(82)90117-6","article-title":"Double-blind controlled trial of topical acyclovir in genital herpes simplex virus infections","volume":"73","author":"Corey","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.annder.2026.103507_b0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jac\/12.suppl_B.67","article-title":"Topical acyclovir in the treatment of genital herpes: a comparison with systemic therapy","volume":"12","author":"Fiddian","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.annder.2026.103507_b0125","first-page":"58","article-title":"Topical acyclovir in the treatment of recurrent herpes simplex virus infections","volume":"47","author":"Kinghorn","year":"1985","journal-title":"Scand J Infect Dis Suppl"},{"key":"10.1016\/j.annder.2026.103507_b0130","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.33.5.649","article-title":"Comparison of intramuscular recombinant alpha interferon (rIFN-2A) with topical acyclovir for the treatment of first-episode herpes genitalis and prevention of recurrences","volume":"33","author":"Levin","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.annder.2026.103507_b0135","doi-asserted-by":"crossref","first-page":"914","DOI":"10.7326\/0003-4819-98-6-914","article-title":"Intravenous acyclovir for the treatment of primary genital herpes","volume":"98","author":"Corey","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annder.2026.103507_b0140","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0002-9343(82)90121-8","article-title":"Intravenous acyclovir in genital herpes. An interim report","volume":"73","author":"Mindel","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.annder.2026.103507_b0145","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0002-9343(88)90578-5","article-title":"Intravenous acyclovir therapy of first episodes of genital herpes: a multicenter double-blind, placebo-controlled trial","volume":"85","author":"Peacock","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.annder.2026.103507_b0150","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00007435-198510000-00009","article-title":"Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir","volume":"12","author":"Corey","year":"1985","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.annder.2026.103507_b0155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/09546639709160279","article-title":"Management of genital herpes in men with 0.5% Aloe vera extract in a hydrophilic cream: a placebo-controlled double-blind study","volume":"8","author":"Syed","year":"1997","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.annder.2026.103507_b0160","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00044011-199816030-00002","article-title":"Treatment of genital herpes in males with imiquimod 1% cream","volume":"16","author":"Syed","year":"1998","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.annder.2026.103507_b0165","first-page":"178","article-title":"Treatment of herpes genitalis with carbenoxolone and cicloxolone creams: a double blind placebo controlled clinical trial","volume":"60","author":"Csonka","year":"1984","journal-title":"Br J Vener Dis"},{"key":"10.1016\/j.annder.2026.103507_b0170","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jama.1982.03330080035025","article-title":"Ineffectiveness of topical idoxuridine in dimethyl sulfoxide for therapy for genital herpes","volume":"248","author":"Silvestri","year":"1982","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.annder.2026.103507_b0175","first-page":"97","article-title":"Effect of recombinant interferon alpha 2 on clinical course of first episode genital herpes infection and subsequent recurrences","volume":"62","author":"Mendelson","year":"1986","journal-title":"Genitourin Med"},{"key":"10.1016\/j.annder.2026.103507_b0180","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/infdis\/156.6.891","article-title":"Leukocyte interferon for treating first episodes of genital herpes in women","volume":"156","author":"Pazin","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.annder.2026.103507_b0185","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1479-828X.1986.tb01576.x","article-title":"Topical interferon cream for the treatment of herpes genitalis: a double-blind controlled trial","volume":"26","author":"Batcheler","year":"1986","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.annder.2026.103507_b0190","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctim.2010.12.003","article-title":"Efficacy of Clinacanthus nutans extracts in patients with herpes infection: systematic review and meta-analysis of randomised clinical trials","volume":"19","author":"Kongkaew","year":"2011","journal-title":"Complement Ther Med"},{"key":"10.1016\/j.annder.2026.103507_b0195","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.annder.2018.07.029","article-title":"Diagnostic and therapeutic recommendations for sexually transmitted diseases: genital herpes","volume":"146","author":"Milpied","year":"2019","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2026.103507_b0200","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejogrb.2018.03.011","article-title":"Prevention and management of genital herpes simplex infection during pregnancy and delivery: guidelines from the French College of Gynaecologists and Obstetricians (CNGOF)","volume":"224","author":"S\u00e9nat","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.annder.2026.103507_b0205","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1097\/AOG.0000000000003840","article-title":"Management of genital herpes in pregnancy ACOG practice bulletin, number 220","volume":"135","author":"Hollier","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.annder.2026.103507_b0210","article-title":"Genital Herpes Simplex (HSV) infection in pregnancy","author":"Ritchie","year":"2020","journal-title":"South Aust Perinat Pract Guidel"},{"key":"10.1016\/j.annder.2026.103507_b0215","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00277-021-04746-y","volume":"101","author":"Henze","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.annder.2026.103507_b0220","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13526","article-title":"Herpes simplex virus infections in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Lee","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.annder.2026.103507_b0225","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1128\/AAC.43.5.1192","article-title":"Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. The Penciclovir Immunocompromised Study Group","volume":"43","author":"Lazarus","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.annder.2026.103507_b0230","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jac\/16.5.621","article-title":"Treatment of recurrent genital herpes simplex infections with oral acyclovir","volume":"16","author":"Ruhneck-Forsbeck","year":"1985","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.annder.2026.103507_b0235","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1086\/339325","article-title":"Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection","volume":"34","author":"Wald","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annder.2026.103507_b0240","first-page":"110","article-title":"Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial","volume":"73","author":"Bodsworth","year":"1997","journal-title":"Genitourin Med"},{"key":"10.1016\/j.annder.2026.103507_b0245","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0149-2918(98)80129-X","article-title":"Advances in the treatment of herpesvirus infection: the role of famciclovir","volume":"20","author":"Tyring","year":"1998","journal-title":"Clin Ther"},{"key":"10.1016\/j.annder.2026.103507_b0250","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1046\/j.1365-2133.2001.04139.x","article-title":"Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial","volume":"144","author":"Chosidow","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2026.103507_b0255","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1086\/339326","article-title":"Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment","volume":"34","author":"Leone","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annder.2026.103507_b0260","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/jac\/44.4.525","article-title":"A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes","volume":"44","author":"Saiag","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.annder.2026.103507_b0265","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.1996.00440140169018","article-title":"A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis","volume":"156","author":"Spruance","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.annder.2026.103507_b0270","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1086\/590561","article-title":"Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial","volume":"47","author":"Abudalu","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annder.2026.103507_b0275","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1185\/03007990802664678","article-title":"Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance","volume":"25","author":"Bodsworth","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.annder.2026.103507_b0280","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1128\/AAC.47.3.1072-1080.2003","article-title":"High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies","volume":"47","author":"Spruance","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.annder.2026.103507_b0285","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1086\/444457","article-title":"Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial","volume":"41","author":"Sacks","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annder.2026.103507_b0290","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1071\/SH08013","article-title":"2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: results of the FaST study","volume":"5","author":"Bodsworth","year":"2008","journal-title":"Sex Health"},{"key":"10.1016\/j.annder.2026.103507_b0295","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1086\/498521","article-title":"Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial","volume":"42","author":"Aoki","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annder.2026.103507_b0300","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1185\/03007990903554471","article-title":"One-day famciclovir vs. placebo in patient-initiated episodic treatment of recurrent genital herpes in immunocompetent Black patients","volume":"26","author":"Leone","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.annder.2026.103507_b0305","doi-asserted-by":"crossref","DOI":"10.53388\/TMR20211125253","article-title":"Efficacy and safety of oral Chinese herbal medicine combined with nucleoside antiviral drugs against recurrent genital herpes: a systematic review and meta-analysis","volume":"7","author":"Liu","year":"2022","journal-title":"Tradit Med Res"},{"key":"10.1016\/j.annder.2026.103507_b0310","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJM198206033062201","article-title":"A trial of topical acyclovir in genital herpes simplex virus infections","volume":"306","author":"Corey","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2026.103507_b0315","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/inf.1985.17.issue-2.07","article-title":"Topical treatment of recurrent genital herpes infections with foscarnet","volume":"17","author":"Wallin","year":"1985","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.annder.2026.103507_b0320","first-page":"247","article-title":"Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study","volume":"62","author":"Barton","year":"1986","journal-title":"Genitourin Med"},{"key":"10.1016\/j.annder.2026.103507_b0325","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0166-3542(92)90044-6","article-title":"Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis","volume":"17","author":"Lebwohl","year":"1992","journal-title":"Antiviral Res"},{"key":"10.1016\/j.annder.2026.103507_b0330","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1128\/AAC.31.7.1137","article-title":"Therapy of genital herpes with topically applied interferon","volume":"31","author":"Eron","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.annder.2026.103507_b0335","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/infdis\/164.4.665","article-title":"Randomized, double-blind, placebo-controlled, clinic-initiated, canadian multicenter trial of topical edoxudine 3.0% cream in the treatment of recurrent genital herpes","volume":"164","author":"Sacks","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.annder.2026.103507_b0340","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/infdis\/161.4.692","article-title":"Randomized, double-blind, placebo-controlled, patient-initiated study of topical high- and low-dose interferon-alpha with nonoxynol-9 in the treatment of recurrent genital herpes","volume":"161","author":"Sacks","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.annder.2026.103507_b0345","first-page":"139","article-title":"Clinical efficacy of ribavirin in the treatment of genital herpes simplex virus infection","volume":"27","author":"Bierman","year":"1981","journal-title":"Chemotherapy"},{"key":"10.1016\/j.annder.2026.103507_b0350","first-page":"312","article-title":"Acyclovir vs isoprinosine (immunovir) for suppression of recurrent genital herpes simplex infection","volume":"68","author":"Kinghorn","year":"1992","journal-title":"Genitourin Med"},{"key":"10.1016\/j.annder.2026.103507_b0355","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1086\/422362","article-title":"Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV","volume":"39","author":"Warren","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annder.2026.103507_b0360","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1258\/0956462021924550","article-title":"Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials","volume":"13","author":"Conant","year":"2002","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.annder.2026.103507_b0365","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1097\/00002030-200006160-00019","article-title":"Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group","volume":"14","author":"Romanowski","year":"2000","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.annder.2026.103507_b0370","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1086\/599991","article-title":"Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial","volume":"200","author":"Mayaud","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.annder.2026.103507_b0375","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jama.1991.03460060079028","article-title":"Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection","volume":"265","author":"Kaplowitz","year":"1991","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.annder.2026.103507_b0380","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/archderm.1993.01680260052005","article-title":"Long-term suppression of recurrent genital herpes with acyclovir. A 5-year benchmark. Acyclovir Study Group","volume":"129","author":"Goldberg","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2026.103507_b0385","first-page":"14","article-title":"Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection","volume":"85","author":"Mertz","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.annder.2026.103507_b0390","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/515385","article-title":"Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study","volume":"178","author":"Reitano","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.annder.2026.103507_b0395","first-page":"220","article-title":"Long-term oral acyclovir treatment prevents recurrent genital herpes","volume":"173","author":"Blom","year":"1986","journal-title":"Dermatologica"},{"key":"10.1016\/j.annder.2026.103507_b0400","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2340\/00015555655963","article-title":"Oral acyclovir suppression of recurrent genital herpes: a double-blind, placebo-controlled, crossover study","volume":"65","author":"Halsos","year":"1985","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.annder.2026.103507_b0405","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/jac\/16.2.219","article-title":"Recurrent genital herpes suppressed by oral acyclovir: a multicentre double-blind trial","volume":"16","author":"Thin","year":"1985","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.annder.2026.103507_b0410","first-page":"387","article-title":"Acyclovir prophylaxis of recurrent genital herpes: randomised placebo-controlled crossover study","volume":"61","author":"Kinghorn","year":"1985","journal-title":"Genitourin Med"},{"key":"10.1016\/j.annder.2026.103507_b0415","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jaad.2007.02.008","article-title":"A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks","volume":"57","author":"Lebrun-Vignes","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2026.103507_b0420","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009036.pub2","article-title":"Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients","author":"Le Cleach","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.annder.2026.103507_b0425","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/OLQ.0b013e31816d1f42","article-title":"An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients","volume":"35","author":"Fife","year":"2008","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.annder.2026.103507_b0430","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.olq.0000243620.13718.56","article-title":"Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life","volume":"34","author":"Handsfield","year":"2007","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.annder.2026.103507_b0435","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.4065\/81.10.1321","article-title":"Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial","volume":"81","author":"Fife","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.annder.2026.103507_b0440","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/105376","article-title":"Once daily valacyclovir for reducing viral shedding in subjects newly diagnosed with genital herpes","volume":"2009","author":"Martens","year":"2009","journal-title":"Infect Dis Obstet Gynecol"},{"key":"10.1016\/j.annder.2026.103507_b0445","first-page":"105","article-title":"Valaciclovir for the suppression of recurrent genital HSV infection: a placebo-controlled study of once daily therapy. International Valaciclovir HSV Study Group","volume":"73","author":"Patel","year":"1997","journal-title":"Genitourin Med"},{"key":"10.1016\/j.annder.2026.103507_b0450","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa035144","article-title":"Once-daily valacyclovir to reduce the risk of transmission of genital herpes","volume":"350","author":"Corey","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2026.103507_b0455","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00007435-200303000-00010","article-title":"Patients\u2019 preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study","volume":"30","author":"Romanowski","year":"2003","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.annder.2026.103507_b0460","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/120347540300700603","article-title":"Oral famciclovir for the suppression of recurrent genital herpes: the combined data from two randomized controlled trials","volume":"7","author":"Tyring","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.annder.2026.103507_b0465","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archinte.1997.00440240109016","article-title":"Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: a multicenter, double-blind, placebo-controlled trial","volume":"157","author":"Mertz","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.annder.2026.103507_b0470","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.280.10.887","article-title":"Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial","volume":"280","author":"Diaz-Mitoma","year":"1998","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.annder.2026.103507_b0475","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jcv.2008.06.004","article-title":"Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial","volume":"43","author":"Bartlett","year":"2008","journal-title":"J Clin Virol"},{"key":"10.1016\/j.annder.2026.103507_b0480","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/01.olq.0000204723.15765.91","article-title":"Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding","volume":"33","author":"Wald","year":"2006","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.annder.2026.103507_b0485","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1258\/0956462011916947","article-title":"Does the extract of the plant Echinacea purpurea influence the clinical course of recurrent genital herpes?","volume":"12","author":"Vonau","year":"2001","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.annder.2026.103507_b0490","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s12602-017-9320-8","article-title":"Comparison of acyclovir and multistrain Lactobacillus brevis in women with recurrent genital herpes infections: a double-blind, randomized, controlled study probiotics","volume":"10","author":"Mohseni","year":"2018","journal-title":"Antimicrob Proteins"},{"key":"10.1016\/j.annder.2026.103507_b0495","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1056\/NEJMoa1301150","article-title":"Helicase-primase inhibitor pritelivir for HSV-2 infection","volume":"370","author":"Wald","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2026.103507_b0500","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1089\/jir.1995.15.625","article-title":"Effect of topical interferon-beta on recurrence rates in genital herpes: a double-blind, placebo-controlled, randomized study","volume":"15","author":"Ophir","year":"1995","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.annder.2026.103507_b0505","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/infdis\/154.3.437","article-title":"Suppression of recurrent genital herpes simplex virus infection with recombinant \u03b12 interferon","volume":"154","author":"Kuhls","year":"1986","journal-title":"J Infect Dis"},{"key":"10.1016\/j.annder.2026.103507_b0510","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciab1056","article-title":"Diagnosis and management of genital herpes: key questions and review of the evidence for the 2021 centers for disease control and prevention sexually transmitted infections treatment guidelines","volume":"74","author":"Johnston","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annder.2026.103507_b0515","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11908-009-0020-8","article-title":"New insights on interactions between HIV-1 and HSV-2","volume":"11","author":"Delany-Moretlwe","year":"2009","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.annder.2026.103507_b0520","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/sti.2008.031153","article-title":"A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers","volume":"84","author":"Cowan","year":"2008","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.annder.2026.103507_b0525","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/infdis\/jit252","article-title":"Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy","volume":"208","author":"Tobian","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.annder.2026.103507_b0530","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1086\/378416","article-title":"Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects","volume":"188","author":"DeJesus","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.annder.2026.103507_b0535","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa062607","article-title":"Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus","volume":"356","author":"Nagot","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2026.103507_b0540","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1097\/QAD.0b013e328010238d","article-title":"Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial","volume":"20","author":"Ouedraogo","year":"2006","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.annder.2026.103507_b0545","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-128-1-199801010-00004","article-title":"Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind, placebo- controlled trial","volume":"128","author":"Schacker","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annder.2026.103507_b0550","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0029-7844(95)00357-6","article-title":"Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes","volume":"87","author":"Scott","year":"1996","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.annder.2026.103507_b0555","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1155\/S1064744902000054","article-title":"Acyclovir suppression to prevent recurrent genital herpes at delivery","volume":"10","author":"Scott","year":"2002","journal-title":"Infect Dis Obstet Gynecol"},{"key":"10.1016\/j.annder.2026.103507_b0560","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1067\/mob.2003.185","article-title":"A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery","volume":"188","author":"Watts","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.annder.2026.103507_b0565","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1471-0528.1998.tb10086.x","article-title":"A randomised placebo-controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection","volume":"105","author":"Brocklehurst","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.annder.2026.103507_b0570","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/j.jogc.2017.04.016","article-title":"208-guidelines for the management of herpes simplex virus in pregnancy","volume":"39","author":"Money","year":"2017","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.annder.2026.103507_b0575","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0301-2115(00)00406-1","article-title":"Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding","volume":"96","author":"Braig","year":"2001","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.annder.2026.103507_b0580","first-page":"1396","article-title":"Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review","volume":"102","author":"Sheffield","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.annder.2026.103507_b0585","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004946.pub2","article-title":"Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection","author":"Hollier","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.annder.2026.103507_b0590","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.AOG.0000219749.96274.15","article-title":"Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial","volume":"108","author":"Sheffield","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.annder.2026.103507_b0595","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ajog.2005.11.051","article-title":"Valacyclovir therapy to reduce recurrent genital herpes in pregnant women","volume":"194","author":"Andrews","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.annder.2026.103507_b0600","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jiac.2015.10.003","article-title":"Polish consensus guidelines on the use of acyclovir in the treatment and prevention of VZV and HSV infections","volume":"22","author":"Szenborn","year":"2016","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.annder.2026.103507_b0605","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/jdv.20450","article-title":"2024 European guidelines for the management of genital herpes","volume":"39","author":"Patel","year":"2025","journal-title":"Acad Dermatol Venereol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963826000414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963826000414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:32:51Z","timestamp":1788985971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963826000414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":121,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0151963826000414"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2026.103507","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2024 guidelines (S3) for the therapeutic management of patients with genital herpes","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2026.103507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103507"}}